TNF-alpha inhibitors and congestive heart failure

Area of Science:

• Immunology
• Cardiology
• Pharmacology

Background:

• Tumor necrosis factor-alpha (TNF-α) is implicated in psoriasis pathogenesis.
• Elevated TNF-α levels are also observed in patients with congestive heart failure (CHF).
• TNF-α inhibitors represent a novel therapeutic class for inflammatory conditions.

Purpose of the Study:

• To evaluate the safety and efficacy of TNF-α inhibitors in patients with CHF.
• To compare the cardiovascular risk profiles of etanercept and infliximab in CHF populations.

Main Methods:

• Review of two large-scale clinical trials on etanercept in over 2000 CHF patients.
• Analysis of a study investigating infliximab use in CHF patients.
• Assessment of mortality, morbidity, and hospitalization data.

Main Results:

• Etanercept treatment in CHF patients showed no increased risk of mortality or morbidity.
• Infliximab use in CHF patients was associated with significantly increased deaths, hospitalizations, and morbidity.
• No FDA warnings exist for etanercept in CHF patients.

Conclusions:

• Etanercept appears to be a safe option for managing inflammatory conditions in CHF patients.
• Infliximab at doses >5 mg/kg is contraindicated in moderate-to-severe CHF (NYHA class III/IV) due to safety concerns.
• Close patient monitoring is essential if infliximab is used at lower doses in CHF patients.